That's a very new process for the EMA, it hasn't really had an im... by Paulo Fontoura

That's a very new process for the EMA, it hasn't really had an impact yet.

Paulo Fontoura

Image Embed Code

Categorized in : Company News

It offers the hope that soon we'll be able to bring ocrelizumab to patients, we feel strongly based on the data that this is a medicine that has the potential to really change the way MS is being treated right now.